192 related articles for article (PubMed ID: 20552736)
1. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Kabaçam G; Törüner M
Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
[No Abstract] [Full Text] [Related]
2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
4. GAIN for loss: adalimumab for infliximab-refractory Crohn disease.
Mannon P
Ann Intern Med; 2007 Jun; 146(12):888-90. PubMed ID: 17577009
[No Abstract] [Full Text] [Related]
5. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
6. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
Haennig A; Bonnet D; Thebault S; Alric L
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
[No Abstract] [Full Text] [Related]
7. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
Cravo M; Silva R; Serrano M
BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
[TBL] [Abstract][Full Text] [Related]
8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab in Crohn's disease - data from real life].
López San Román A; Van Domselaar M; Garrido E
Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
[No Abstract] [Full Text] [Related]
10. Commentary: infliximab or adalimumab in Crohn's disease?
Sprakes MB; Hamlin PJ
Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
[No Abstract] [Full Text] [Related]
11. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
Schreiber S
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
Abreu MT
Rev Gastroenterol Disord; 2007; 7 Suppl 1():S20-6. PubMed ID: 17392630
[TBL] [Abstract][Full Text] [Related]
13. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
Lopez-Sanroman A; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
[No Abstract] [Full Text] [Related]
14. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
15. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
Tursi A; Elisei W; Picchio M; Penna A
Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
[No Abstract] [Full Text] [Related]
16. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
17. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
18. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
19. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
